CHRNA7 and hepatocellular carcinoma: Thus, therapeutic or molecular inhibition of the α7-nAChR could prohibit oncogenic and metastatic processes, such as evasion of apoptosis, the EMT, migration, and invasion, as demonstrated in our study where the α7-nAChR promoted cell viability, metastasis, and CSCs-like phenotypes in HCC (Figure 3).